ValuEngine upgraded shares of Interpace Diagnostics Group (NASDAQ:IDXG) from a strong sell rating to a sell rating in a report released on Friday morning.

Separately, Maxim Group reissued a buy rating and issued a $5.00 price objective on shares of Interpace Diagnostics Group in a report on Tuesday, November 14th.

Interpace Diagnostics Group (NASDAQ IDXG) opened at $0.98 on Friday. The stock has a market capitalization of $26.85, a PE ratio of 0.35 and a beta of 1.64. Interpace Diagnostics Group has a fifty-two week low of $0.72 and a fifty-two week high of $4.45.

Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings data on Monday, November 13th. The business services provider reported ($0.15) earnings per share (EPS) for the quarter. The company had revenue of $4.20 million during the quarter. Interpace Diagnostics Group had a negative net margin of 6.33% and a negative return on equity of 5.69%.

An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Sabby Management LLC acquired a new stake in Interpace Diagnostics Group Inc (NASDAQ:IDXG) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 529,819 shares of the business services provider’s stock, valued at approximately $476,000. Sabby Management LLC owned 2.39% of Interpace Diagnostics Group as of its most recent SEC filing. Institutional investors and hedge funds own 5.69% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Interpace Diagnostics Group (IDXG) Lifted to “Sell” at ValuEngine” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with's FREE daily email newsletter.